We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Week in JAMA |

This Week in JAMA FREE

JAMA. 2005;293(17):2061. doi:10.1001/jama.293.17.2061.
Text Size: A A A
Published online


Understanding the natural history of localized prostate tumors is important to support treatment recommendations. In this issue of JAMA, Albertsen and colleaguesArticle report 20-year mortality outcomes for men with localized disease who were treated with observation or androgen withdrawal therapy. In analyses stratified for age and tumor grade, the authors found a minimal risk of prostate cancer death in men with low-grade tumors (Gleason score 2-4), a high risk in men with high-grade tumors (Gleason score 8-10), and an intermediate risk in men with tumors of Gleason score 5 or 6. In an editorial,Article Gann and Han discuss the relevance of these data for contemporary prostate cancer patients.


Bone mineral density (BMD) predicts fracture risk in white women, but whether the relationship is similarly applicable to black women is not clear. Cauley and colleaguesArticle examined the association of BMD with risk of nonspinal fractures in white and black women in a large prospective cohort study. In age-adjusted models, they found that black women have a lower risk of fracture than white women at every level of BMD. In multivariable analyses, the lower risk of fracture in black vs white women was independent of BMD and other factors commonly associated with bone health. In an editorial,Article Acheson discusses the limitations of race-based norms for BMD, factors that may explain differences in fracture risk, and the importance of individual clinical assessment.


Sirolimus-eluting stents are associated with better outcomes than bare-metal stents after primary coronary intervention, but there are few data on their efficacy for patients with acute myocardial infarction. Valgimigli and colleaguesArticle evaluated clinical outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI) who were randomly assigned to receive either single high-dose bolus tirofiban-supported sirolimus-eluted stent implantation or abciximab pretreatment and bare-metal stent placement. Patients in the tirofiban plus sirolimus-eluting stent group were significantly less likely to experience death, nonfatal myocardial infarction, stroke, or binary restenosis at 8 months compared with patients in the abciximab plus bare-metal stent group. In an editorial,Article Cohen and Ohman review the extant data on drug-eluting stents in the setting of acute myocardial infarction.


Acupuncture is used to prevent migraine attacks, but data on its effectiveness are scarce. Linde and colleagues randomly assigned patients with migraine headaches to 8 weeks of acupuncture or sham acupuncture treatments or to a waiting list (control) and assessed the number of days with moderate or severe headache reported in headache diaries for the 4 weeks before vs 9 to 12 weeks after randomization and treatment. They found that days with headache declined significantly and similarly for patients receiving actual or sham acupuncture compared with control patients.

See Article


State-of-the-art patient care and laboratory facilities in the newly opened $596 million Mark O. Hatfield Clinical Research Center at the National Institutes of Health will help researchers conduct clinical trials and transform laboratory research into clinical advances.

See Article


Incidence, predictors, and clinical outcomes 9 months after implantation of drug-eluting stents.

See Article


Structure, operation, and early results of a multidisciplinary, clinically based, postmarketing surveillance and information dissemination system for serious and previously unrecognized adverse drug reactions (ADRs).

See Article


Clinical Review
Routine episiotomy offers neither short-term nor long-term benefits.

See Article


For your patients: Information about childbirth.

See Article



Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...